The U.S. Food and Drug Administration today approved a new indication for three cardiac resynchronization therapy defibrillators (CRT-D) used to treat certain heart failure patients. The new use is for patients with an abnormality known as left bundle branch block, which occurs when there is delayed activation and contraction of the left ventricle. The three devices, all manufactured by Boston Scientific Corp., are intended to treat patients with left bundle branch block who have either mild heart failure or heart failure with no apparent symptoms.
The CRT-D device combines two functions. As an implantable cardioverter defibrillator (ICD) it senses dangerous abnormal heart rhythms and then attempts to shock the heart back into a normal rhythm. As cardiac resynchronization therapy, it generates small electrical impulses to coordinate the beating of the left and right ventricles so that they work together more effectively to pump blood throughout the body.
CRT-Ds are to be used as an addition to, not a replacement for, heart failure drug therapy.
“This approval allows heart failure patients with left bundle branch block to benefit from this therapy," said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “The FDA is pleased to safely make this new technology available for a greater number of heart failure patients."
The FDA based its approval on the results of the 1,820-patient Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) clinical study. The study which followed 1,820 patients for an average of nearly three years at 110 centers in the United States, Europe, Canada, and Israel. It compared CRT-D therapy to ICD-only therapy in specific heart failure patients to determine whether it reduced the risk of death and heart failure. In patients with left bundle branch block, who represented 70 percent of the study group, CRT-D showed a reduction in the risk of death and heart failure by 57 percent, as compared to ICD alone.
The rate of complications was considered to be acceptable by the FDA for this device, however, physicians should adequately inform patients about potential complications.
As a condition of FDA approval, Boston Scientific must conduct two post-approval studies. One study will evaluate complications and long-term mortality benefits of CRT-D in patients with left bundle branch block identified through the National Cardiovascular Data Registry. The other will follow patients from the original MADIT-CRT clinical study every six months for five years to assess long-term mortality benefits of CRT-D vs. ICD.
-----
Community News You Can Use
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Friday, September 17, 2010
FDA approves devices for heart failure patients
Posted by
Georgia Front Page.com
at
10:56 AM
0
comments
Labels: approval, cardiac, crt-d, defibrillators, device, failure, fayette front page, fda, georgia, georgia front page, heart
Tuesday, September 14, 2010
Gene Therapy Proves Effective in Treating Severe Heart Failure; Holds Potential to Drastically Reduce Healthcare Costs for Heart Failure Patients
/PRNewswire/ -- The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion titled "Latest Developments in Stem Cell and Gene Therapy in Heart Failure" which includes a presentation by Dr. Roger Hajjar, Director of the Cardiovascular Research Institute, one of the 12 translational science institutes at The Mount Sinai Medical Center in New York. Dr. Hajjar's discussion will focus on the injection of a gene into patients with advanced heart failure to reverse the debilitating and life-threatening condition.
Over ten years, Dr. Hajjar and his team have validated the cardiac sarcoplasmic reticulum calcium ATPase pump, SERCA2a, as a target in heart failure and developed methodologies for cardiac-directed gene transfer. This work has led to the initiation and recent completion of phase 1 and phase 2 First-in-Man clinical trials of SERCA2a gene transfer in patients with advanced heart failure.
Patients treated with high dose therapy have shown 90 percent risk reduction for heart failure-related cardiovascular events such as significantly worsening health, the need for a transplant or cardiovascular device support, intravenous treatment or death.
"The patients receiving this gene therapy have shown marked improvements," said Dr. Hajjar. "Through our tests we've observed heart failure patients' quality of life improves greatly for significantly less cost than traditional therapies."
Patients treated with the gene therapy treatment may result in a large decrease in personal health care costs across their trial period. In nine months, individuals treated with the trial's placebo spent an average of $27,118 on health care, paying for expenses such as hospital stays, emergency medicine, and home care. Comparatively, in the same period of time, individuals treated with gene therapy spent an average of $329 on health care.
"Gene Therapy is a breakthrough in the treatment of heart failure patients that holds the potential to reverse the disease while also making treatment and recovery more affordable than ever," said Dr. Douglas Mann, HFSA President. "It is critical for the medical community to continue to integrate science and clinical medicine so biomedical research can improve patient care."
-----
Community News You Can Use
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Posted by
Georgia Front Page.com
at
9:16 AM
0
comments
Labels: failure, fayette front page, gene, georgia, georgia front page, heart, research, therapy, treatment
Tuesday, August 24, 2010
Study Compares Risk With Two Diabetes Drugs
/PRNewswire/ -- In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same - about 4 percent - for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.
"This study provides patients and their doctors with another source of information about rosiglitazone and pioglitazone (sold as Avandia and Actos, respectively) as they determine the best therapy for diabetes patients," said Debra Wertz, Pharm.D., lead author and outcomes research manager at HealthCore, Inc., the research subsidiary of health insurance company WellPoint, Inc.
This study evaluated more than 36,000 diabetes patients. Of the 28,938 patients who were propensity-score matched, a methodology used to provide an estimation of treatment-effects that is as unbiased as possible, 602 patients taking rosiglitazone and 599 taking pioglitazone over a 33-month period suffered either a heart attack, heart failure, both, or died. This translates to about 4 percent of all patients taking either medication. The individual specific adverse events were also not significantly different between the two groups, and were:
-- Heart attack - 96 patients on rosiglitazone and 121 patients on
pioglitazone;
-- Heart failure - 265 patients taking rosiglitazone and 243 taking
pioglitazone;
-- Heart attack and heart failure - 24 patients on rosiglitazone and 18
on pioglitazone; and
-- Death - 217 patients taking rosiglitazone and 217 taking pioglitazone.
The study included 36,628 patients who had submitted insurance claims to WellPoint affiliates for either of the two diabetes medications between 2001 and 2005. Patients' average age was 54, and 58 percent were male. Wertz and her team obtained death records from the National Death Index, a central database administered by the National Center for Health Statistics.
The investigators divided patients into two equal groups, one receiving rosiglitazone and the other, pioglitazone. After adjusting the data for (removing/minimizing the effect of) age, gender, prior heart and blood vessel diseases and diabetes-related complications and severity indicators, they compared the incidence of heart attack, heart failure and death for an average 14 months of treatment and 19 months of post-treatment follow-up.
Diabetes is a disease in which the body cannot adequately produce the hormone insulin or uses it improperly. The disease can cause a potentially dangerous buildup of sugar in the blood and also increases the risk of heart and blood vessel diseases, which are the main causes of death for people with diabetes.
Rosiglitazone, sold under the trade name Avandia by GlaxoSmithKline, and pioglitazone, sold as Actos by Takeda Pharmaceuticals, belong to the same class of drugs, called TZDs or thiazolidinediones. They help the body use insulin more effectively by boosting the body's sensitivity to the hormone and thus help control blood sugar.
This study has results different from earlier ones that found a greater risk of heart attack among rosiglitazone users compared to patients on other treatments or placebo. In 2007, the Food and Drug Administration decided that the benefits of rosiglitazone outweighed the risks, and it remained on the market although its use decreased significantly. In July 2010, an FDA advisory committee again reviewed numerous studies, including this study, and recommended that rosiglitazone remain on the market, although with additional warnings or restrictions. The FDA has not yet ruled on this latest recommendation.
"Besides its findings that rosiglitazone and pioglitazone have comparable risks, what distinguishes this latest study from other claims-based analyses is its analysis of death records, which include out-of-hospital deaths," Wertz said. The study also followed patients for a longer period of time than some of the earlier research, according to the investigators.
"One of the reasons we embarked on this analysis was to see if there were any differences in effect that we could identify between these two agents," said Mark J. Cziraky, Pharm.D., study co-author, and vice president of research development and operations at HealthCore. "We did not find that with the approach and methods we took within this population."
Other co-authors are Chun-Lan Chang, Ph.D.; Chaitanya A Sarawate, M.S.; Vincent J. Willey, Pharm.D.; and Rhonda L. Bohn, M.P.H., Sc.D.
Author disclosures are on the manuscript. WellPoint, Inc. funded this research.
An accompanying editorial, "Improving Surveillance for Drug Safety: Lessons from Rosiglitazone," by Frederick A Masoudi, M.D., M.S.P.H., is available.
Statements and conclusions of study authors published in American
Heart Association scientific journals are solely those of the study
authors and do not necessarily reflect the association's policy or
position. The association makes no representation or guarantee as to
their accuracy or reliability. The association receives funding
primarily from individuals; foundations and corporations (including
pharmaceutical, device manufacturers and other companies) also make
donations and fund specific association programs and events. The
association has strict policies to prevent these relationships from
influencing the science content. Revenues from pharmaceutical and
device corporations are available at http://www.americanheart.org/
corporatefunding.
-----
Community News You Can Use
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Posted by
Georgia Front Page.com
at
4:07 PM
0
comments
Labels: actos, attack, avandia, death, diabetes, failure, fayette front page, georgia, georgia front page, heart, piogliatzone, report, rosiglitazone, therapy
Thursday, June 3, 2010
Medicare Meltdown Looming As Steep Medicare Cut Begins
/PRNewswire/ -- The U.S. Senate's failure to act before this week's 21 percent Medicare physician payment cut has put seniors' health care at grave risk. A new American Medical Association (AMA) physician survey shows that many physicians are already limiting the number of Medicare patients they treat. The AMA today launched a multi-million dollar national advertising campaign, with ads on TV and radio and in newspapers, including The New York Times, USAToday and The Wall Street Journal.
"The Senate has turned its back on our nation's seniors and the physicians who care for them by leaving for vacation and failing to stop a 21 percent Medicare cut before their self-imposed June 1 deadline," said AMA President J. James Rohack, M.D. "Today, the AMA is unveiling a new multi-million dollar ad campaign encouraging the public to contact their Senators and tell them to get back to work and fix Medicare now."
The 21 percent cut also hurts our nation's military families, as TRICARE rates are tied to Medicare. "It is sad and ironic that Senators raced home to celebrate Memorial Day without first voting to preserve health care for active duty military families," Dr. Rohack said.
Yesterday, the AMA received a call from Joan, a retired nurse, who was looking for a Maryland physician for her 72-year-old sister and could not find one who took Medicare. Both physician offices she called said that as of this June 1 they were no longer accepting new Medicare patients -- a real life example of how decisions made in Washington hurt real people.
Our new online survey of 9,000 physicians who care for Medicare patients confirms that seniors are already being hurt by Congress' mismanagement of the Medicare program. About one in five physicians (17%) say they have already been forced to limit the number of Medicare patients in their practice. Nearly one-third of primary care physicians (31%) have already been forced to take that action. The top two reasons physicians gave for these actions were the ongoing threat of future cuts and the fact that Medicare payment rates were already too low.
"Make no mistake: Physicians want to care for seniors and military families, but the chronic instability caused by the threat of future payment cuts has already taken its toll - and a 21 percent cut will make matters much worse," Dr. Rohack said.
"This is the third time this year that Congress has allowed a Medicare deadline to expire without action," Dr. Rohack said. "Each time Congress delays fixing the Medicare physician payment cut makes the problem worse and the price tag higher for the American taxpayer. Enough is enough. The Senate needs to fix the Medicare physician payment system for America's seniors once and for all."
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Posted by
Georgia Front Page.com
at
3:42 PM
0
comments
Labels: cut, failure, fayette front page, georgia, georgia front page, health, medicare, military, payment, senate, seniors, taxpayer, tricare
Sunday, November 15, 2009
Cardiac Science Notifies AED Customers of Nationwide Voluntary Medical Device Correction
Cardiac Science Corporation [NASDAQ: CSCX] is initiating a voluntary field correction after it was determined certain automated external defibrillators (AEDs) may experience a rare product issue in which the AED may not be able to deliver therapy during a resuscitation attempt. Device failure may affect resuscitation of the patient, which could lead to serious adverse events or death. These AEDs have electronic components which may fail and the failure may not be detected by the device's periodic self-tests. The affected models include the Powerheart 9300A, 9300C, 9300D, 9300E, 9300P, 9390A, 9390E, and CardioVive 92531, 92532, and 92533 devices.
Cardiac Science has received a total of 64 complaints concerning four resistors within certain AEDs. Two of these complaints were associated with a failure to deliver therapy. This issue is predicted to occur in approximately one in 75,000 AEDs manufactured between August 2003 and August 2009. The company has also received 114 complaints regarding "Service Required" messages resulting from a specific relay switch failure. There have been no reported instances where this issue has resulted in an inability to deliver therapy.
Until a correction is available in May, 2010, the company strongly advises customers to check the status indicator on the front of the AED and follow the procedures documented in the materials accompanying the AED. The company advises that customers leave their AEDs in service.
"When customers choose a product from Cardiac Science, they expect outstanding reliability," said Dave Marver, president and chief executive officer. "We understand the role our products play in public health and are taking appropriate measures to further improve the performance of our products."
The company has implemented more stringent testing of the components and all AEDs produced since August, 2009 are unaffected. Customers in possession of an AED that may exhibit either of these issues will be notified immediately. A software update to address the resistor issue will be available by May, 2010. This software update will enhance the AED's self-test capabilities and improve detection of the issue. In the interim, the company advises customers to keep their AEDs in service and follow the normal testing and maintenance procedures found in the Operator and Service Manual. A copy of these procedures is available at www.cardiacscience.com/AED175. At this site, customers may confirm if their AED is affected and register for automatic e-mail reminders to conduct scheduled maintenance.
If the AED is not rescue ready (the indicator is red) customers should contact the company immediately at 425.402.2000 (option 1) within the United States. Outside the US contact +44.161.926.0011 or the local Cardiac Science representative. Customers can also email the company at AED175@cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements. The word "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, predictions of AED component failure rates, the availability of software updates to improve detection of the component issue, and the effectiveness of the planned software update. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2008, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:32 AM
0
comments
Labels: AED, cardiac, correction, defibrillators, failure, fayette, fayette front page, georgia, georgia front page, ready, rescue, resuscitation, therapy
Wednesday, November 4, 2009
Statins May Worsen Symptoms in Some Cardiac Patients
/PRNewswire/ -- Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance.
"Systolic heart failure is most often due to coronary artery disease and appears to have more of an inflammatory component than diastolic heart failure," said Lawrence P. Cahalin, PhD, PT, Northeastern University, Boston, MA. "It is possible that statins would help patients with systolic heart failure more than patients with diastolic heart failure due to the cholesterol-lowering and anti-inflammatory effects of statins."
Researchers from Northeastern University and Massachusetts General Hospital, Boston, MA, retrospectively reviewed the charts of 136 patients with heart failure in order to examine the effect of statins on pulmonary function (PF) and exercise tolerance (ET) in patients with DHF vs. SHF. A non-statin group (82 percent of patients had DHF) of 75 patients was compared with a statin group (72 percent of patients had DHF) of 61 patients. Atorvastatin was prescribed in 75 percent of the patients on statins.
Results of the analysis showed that overall PF and ET of patients in the statin group were significantly lower than patients in the non-statin group. Further subgroup analyses revealed that PF measures in the DHF statin group were 12 percent lower than PF measures in the DHF non-statin group. Furthermore, the amount of exercise performed by patients with DHF who were on a statin was almost 50 percent less than patients with DHF not on a statin.
"Some patients with diastolic heart failure may be more prone to the adverse effect of statins on muscle. It may be that patients with particular preexisting factors will experience unfavorable results from statin therapy, including exercise intolerance, dyspnea, and fatigue," said Dr. Cahalin.
Although the PF and ET measures in the SHF statin group were not significantly greater than in the SHF non-statin group, the PF measures were 11 percent to 14 percent higher, and the peak ET measures were 2 percent to 7 percent higher than the PF and ET measures of the SHF non-statin group, suggesting that statins did benefit patients with SHF.
"Not all statins are alike and not all patients are alike. Some statins are stronger than others and are likely to act differently, given particular patient characteristics, and produce different degrees of wanted and unwanted effects," said Dr. Cahalin. "In our continuing study, we hope to identify patient characteristics that are associated with favorable and less than favorable results from statin therapy."
Although the new data suggest that statins may actually worsen symptoms in patients with DHF, researchers feel that the benefits of using statins in patients with SHF and DHF outweigh the risks.
"Due to beneficial effects on lipids and other cardiovascular factors, statins are becoming a standard treatment for many patients with or without systolic or diastolic heart failure. It is likely that the use of statins for these conditions will continue to increase," said Dr. Cahalin. "However, if patients taking a statin are short of breath, fatigued, and unable to exercise or perform functional tasks, then exams of muscle strength and endurance, as well as pulmonary function and exercise tolerance, are warranted."
"Statins provide significant benefits for patients with cardiovascular disease," said Kalpalatha Guntupalli, MD, FCCP, President of the American College of Chest Physicians. "However, as for any new medication prescribed, clinicians should closely monitor the effects that different types of statins have on individual patients."
CHEST 2009 is the 75th annual international scientific assembly of the American College of Chest Physicians, held October 31-November 5 in San Diego, CA. The ACCP represents 17,400 members who provide patient care in the areas of pulmonary, critical care, and sleep medicine in the United States and throughout the world. The ACCP's mission is to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication. For more information about the ACCP, please visit the ACCP Web site at www.chestnet.org.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:34 AM
0
comments
Labels: attacks, cardiac, cardiovascular, failure, fayette, fayette front page, georgia, georgia front page, heart, statin, study
Monday, November 2, 2009
FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.
From April 2005 through October 2008, the FDA received 78 reports of problems with kidney function in patients using Byetta. Some cases occurred in patients with pre-existing kidney disease or in patients with one or more risk factors for developing kidney problems.
Nearly 7 million prescriptions for Byetta were dispensed between April 2005 and September 2008. The 78 cases represent a small percentage of the total number of patients using the drug to control blood sugar (glucose) levels.
The most common side effects associated with Byetta include nausea, vomiting, and diarrhea. These side effects may have contributed to the development of altered kidney function. Kidney malfunction can result in a build-up of waste products in the blood, leading to serious illness or life-threatening conditions.
“Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems,” said Amy Egan, M.D. M.P.H., of the Division of Metabolism and Endocrinology Products at the FDA’s Center for Drug Evaluation and Research. “Patients also should be aware that problems with kidney function could lead to changes in urine color, frequency of urination or the amount of urine, unexplained swelling of the hands or feet, fatigue, changes in appetite or digestion, or dull ache in mid to lower back.”
Patients who experience any of these symptoms should immediately discuss them with their health care professional.
To help health care professionals and patients better weigh the known risks and benefits of Byetta, the FDA worked with the manufacturer to update the drug’s prescribing information (label). A description of these label changes can be found online.
Byetta is manufactured by San Diego-based Amylin Pharmaceuticals Inc.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:45 PM
0
comments
Labels: byetta, diabetes, failure, fayette front page, fda, georgia, georgia front page, kidney, treatment
Thursday, October 22, 2009
'Doc Buy' Fails as Physician Support for Health Care Overhaul Wanes - Shadow Bill Concealing $247 Billion in Health Costs Defeated
'Doc Buy' Fails as Physician Support for Health Care Overhaul Wanes - Shadow Bill Concealing $247 Billion in Health Costs Defeated in Critical Senate Vote
/Standard Newswire/ -- Patients First, A Project of Americans for Prosperity(tm) is praising the U.S. Senate's bipartisan rejection of the $247 billion so-called "Doc Fix" bill (S.1776) by a 53-47 margin.
Senate Majority Leader Harry Reid had attempted to hastily force the bill through the Senate to
simultaneously purchase the support of doctors in the larger health care legislative battle, while concealing the full cost of the health overhaul in a shadow bill.
Leader Reid had abruptly scheduled today's failed cloture vote to increase Medicare payments to doctors by $247 billion. The tricky tactic, which would also have required a vote to waive Senate budget rules, raised criticism since it would conceal the total cost of the health care plan being considered in Congress by splitting the overhaul into two separate bills. The Senate Finance Committee recently voted for a $904 billion plan, but the addition of this $247 billion bill would have pushed the total cost of the overhaul to well over $1.1 trillion, violating the White House's
pledge to keep the health care plan deficit neutral.
"The 53 Senators that voted against this hastily-crafted backroom health care deal deserve credit," said Phil Kerpen, policy director of Patients First. "Leader Reid's attempt to use outright deception and trickery to conceal the true costs of the attempted Washington takeover of health care has failed. Americans have the right to know the details of how government-forced health care would impact their access to quality affordable health care. Transparency and open debate, not backroom deals and legislative gimmicks, offer us a way forward towards real health care
reform."
The "Doc Fix" bill's defeat spells further trouble for the Obama Administration and Congressional Democrats as they court critical support from doctors for the controversial health care overhaul. A recent IBD/TIPP Poll of nearly 1,400 doctors found that two-thirds of
physicians oppose the reforms proposed by Congress. 45 percent of doctors said that enactment
would force them to consider retiring or abandoning their practice, and 67 percent anticipated fewer medical school applicants. Meanwhile, 65 percent of doctors believed that the plan would lead to lower-quality care for seniors and 71 percent said that it was impossible for government to insure 47 million more Americans while cutting costs and providing better quality care.
"America's doctors cannot be bribed into supporting legislation that will restrict patient choice, increase bureaucracy, defund Medicare for seniors, and drive costs so high that middle class taxpayers suffer," said Phil Kerpen. "Our nation's physicians want to care for their patients, and government should not stand in the way of the sacred doctor-patient relationship."
Patients First, A Project of Americans for Prosperity(tm), is focused on real health care reform--reform that puts patients first. Patients First believes that Americans want and need more health insurance options--not just a costly, government-defined plan paid for by American taxpayers.
Patients First is a project of Americans for Prosperity® (AFP), a 501(c)(4) non-profit organization recognized by the IRS. AFP is the nation's premier grassroots organization committed to advancing every individual's right to economic freedom and opportunity. AFP has more than 700,000 members, including members in all 50 states, and 25 state chapters. Patients First is not affiliated in any way with Patient First health clinics. For more information on Patients First, go to www.JoinPatientsFirst.com (http://rs6.net/tn.jsp?et=1102780163328&s=13633e=001ZT5NIGsO3Sm71FnQxFM7c909urFNCe1BrHFUUxAchDovoi3PcvaYNpHK1T8
3srDskHtH9Wp_AWd5JxMhq2QGU6eumkYedekDD05_3N4yT1ANSouKAwNgOyU__ZtAVjIv).
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia
Posted by
Georgia Front Page.com
at
12:02 PM
0
comments
Labels: atlanta, bill, cloture, defeat, doc buy, failure, fayette front page, fayetteville, georgia, georgia front page, health care, medicare, patients, payments, peachtree city, S1776, shadow
Monday, February 11, 2008
Piedmont Fayette Hospital and Piedmont Newnan Hospital Celebrate American Heart Month With Free Dessert and Discussion Events
Cardiovascular diseases, including stroke, are the nation’s No. 1 killer, according to the American Heart Association. Join Piedmont Fayette Hospital and Piedmont Newnan Hospital for two dessert and discussion events featuring local cardiologists.
Piedmont Fayette Hospital will host a discussion on "Congestive Heart Failure," led by cardiologist Bukola Olubi, M.D., on Thursday, Feb. 21 at 6:30 p.m. in Conference Room C in the hospital’s 1279 building. To make reservations call 770-719-6060.
Piedmont Newnan Hospital will host a discussion on "Living Heart Healthy," on Thursday Feb. 28 at 6:30 p.m., led by cardiologist George J. Vellanikaran, M.D., in the Special Events Center at 299 Bullsboro Drive in Newnan. To make reservations call 678-854-2471.
Registration for both programs is free and refreshments and door prizes will be provided. For more information on Piedmont Fayette Hospital’s and Piedmont Newnan Hospital’s cardiology services, please visit www.fayettehospital.org or www.piedmontnewnan.org.
Posted by
Georgia Front Page.com
at
5:53 PM
0
comments
Labels: congestive, county, coweta, failure, fayette county, fayette front page, fayette hospital, heart, hospital, newnan, peachtree city, piedmont, tyrone